Comparison between Infinium Pharmachem IPO and Maiden Forgings IPO.
Infinium Pharmachem IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Maiden Forgings IPO is a SME Bookbuilding proposed to list at BSE SME.
| Infinium Pharmachem IPO | Maiden Forgings IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Swastika Investmart Ltd. | Share India Capital Services Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Maashitla Securities Pvt.Ltd. |
| Market Maker | Swastika Investmart Ltd. | Share India Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Infinium Pharmachem IPO is up to ₹23.99 Cr whereas the issue size of the Maiden Forgings IPO is up to ₹22.64 Cr. The final issue price of Infinium Pharmachem IPO is ₹135.00 per share and of Maiden Forgings IPO is ₹63.00 per share.
| Infinium Pharmachem IPO | Maiden Forgings IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹60.00 per share | |
| Issue Price (Upper) | ₹63.00 per share | |
| Issue Price (Final) | ₹135.00 per share | ₹63.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹13.50 per share | |
| Market Lot Size | 1000 shares | 2000 shares |
| Fresh Issue Size | 17,81,000 shares | 35,94,000 shares |
| Fresh Issue Size (Amount) | up to ₹23.99 Cr | up to ₹22.64 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 17,81,000 shares | 35,94,000 shares |
| Issue Size Total (Amount) | up to ₹23.99 Cr | up to ₹22.64 Cr |
Infinium Pharmachem IPO opens on Mar 31, 2023, while Maiden Forgings IPO opens on Mar 23, 2023. The closing date of Infinium Pharmachem IPO and Maiden Forgings IPO is Apr 05, 2023, and Mar 27, 2023, respectively.
| Infinium Pharmachem IPO | Maiden Forgings IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Mar 31, 2023 | Mar 23, 2023 |
| Issue Close | Apr 05, 2023 | Mar 27, 2023 |
| Basis Of Allotment (Tentative) | Apr 11, 2023 | Mar 31, 2023 |
| Initiation of Refunds (Tentative) | Apr 12, 2023 | Apr 03, 2023 |
| Credit of Share (Tentative) | Apr 13, 2023 | Apr 05, 2023 |
| Listing date (Tentative) | Apr 17, 2023 | Apr 06, 2023 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Infinium Pharmachem IPO P/E ratio is 7.83, as compared to Maiden Forgings IPO P/E ratio of 8.38.
| Infinium Pharmachem IPO | Maiden Forgings IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Standalone)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.05 | 73.37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 7.83 | 8.38 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹93.93 Cr. | ₹89.54 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 43.85 | 6.87 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 72 | 16.97 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.91 | 0.66 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹54.13 | ₹4.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 46.61 | 6.87 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Infinium Pharmachem IPO Retail Individual Investors (RII) are offered 8,70,000 shares while in Maiden Forgings IPO retail investors are offered 8,70,000 shares. Qualified Institutional Buyers (QIB) are offered in Infinium Pharmachem IPO and 3,60,000 shares in Maiden Forgings IPO.
| Infinium Pharmachem IPO | Maiden Forgings IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 94,000 shares | 1,90,000 shares |
| QIB | 3,60,000 shares | |
| NII | 8,70,000 shares | 9,70,000 shares |
| RII | 8,70,000 shares | 22,64,000 shares |
| Employee | 41,000 shares | |
| Others | ||
| Total | 17,81,000 shares | 35,94,000 shares |
Infinium Pharmachem IPO subscribed 1.92x in total, whereas Maiden Forgings IPO subscribed 1.20x.
| Infinium Pharmachem IPO | Maiden Forgings IPO | |
|---|---|---|
| QIB (times) | 1.00x | |
| NII (times) | 1.94x | 1.42x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 2.00x | 1.12x |
| Employee (times) | 1.29x | |
| Other (times) | ||
| Total (times) | 1.92x | 1.20x |
